Arcutis Adds Biopharma Veteran Chris Peetz to Board Amid Growth Push
Event summary
- Arcutis Biotherapeutics appointed Chris Peetz to its Board of Directors effective July 15, 2026.
- Peetz is the CEO of Mirum Pharmaceuticals and has a track record in biopharma leadership and strategic acquisitions.
- Arcutis aims to leverage Peetz's experience to grow its ZORYVE franchise and expand into new indications.
- ZORYVE is the top prescribed branded topical therapy for atopic dermatitis, seborrheic dermatitis, and plaque psoriasis.
The big picture
Arcutis' appointment of Chris Peetz reflects its strategic focus on scaling its commercial franchises and expanding its pipeline through acquisitions. Peetz's background in leading biopharma companies through growth phases aligns with Arcutis' goals to enhance its ZORYVE franchise and explore external innovation. This move comes at a pivotal time as the company seeks to maintain its leadership position in the immuno-dermatology space.
What we're watching
- Strategic Expansion
- How Peetz's expertise in scaling biopharma companies will impact Arcutis' growth strategy.
- Pipeline Development
- Whether Arcutis can successfully expand ZORYVE into new indications under Peetz's guidance.
- Market Positioning
- The pace at which Arcutis can solidify its position as a leader in immuno-dermatology.
Related topics